
    
      This is a multicenter, randomized, open-label Phase 2 study designed to evaluate safety and
      tolerability and preliminary efficacy of VS-6766 versus VS-6766 in combination with
      defactinib in subjects with molecularly profiled recurrent LGSOC.
    
  